Program
canvuparatide
Also written as “MBX 2109”, “Canvuparatide” and “MBX 2109 (Part A)”.
Its studies are mostly in Hypoparathyroidism · Renal Insufficiency, led by MBX Biosciences.
Furthest: phase 3, since Jul 7, 20264 company-led studies, 1 open or runningNext primary completion: Jan 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MBX Biosciences | 41 open or running | phase 3since Jul 7, 2026 | Dec 2, 2021 | Jan 2028phase 3 · NCT07699471 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 2, 2021First study: phase 1 study in HealthyFirst studyNCT05158335 · 76 enrolled · United States
- Jun 12, 2024Phase 1 study in Renal InsufficiencyNCT06496217 · 25 enrolled · United States
- Jun 13, 2024Phase 2 study in HypoparathyroidismNCT06465108 · 64 enrolled · United States, Argentina, Turkey (Türkiye)
- Jul 7, 2026Phase 3 study in HypoparathyroidismPhase 3 reachedNCT07699471 · 160 planned · United States, Canada
Ahead
- Jan 2028Primary completion: phase 3 study in HypoparathyroidismNCT07699471
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07699471Hypoparathyroidism · United States, Canada | 3 | Recruiting | Jan 2028 | 160 |
| NCT06465108Hypoparathyroidism · United States, Argentina, Turkey (Türkiye) | 2 | Completed | May 23, 2025 | 64 |
| NCT06496217Renal Insufficiency · United States | 1 | Completed | Sep 4, 2025 | 25 |
| NCT05158335Healthy · United States | 1 | Completed | Jun 20, 2023 | 76 |
How it is read
Names in the registry
- “MBX 2109”, 5 entries
- “Canvuparatide”, 1 entry
- “MBX 2109 (Part A)”, 1 entry
- “MBX 2109 (Part B)”, 1 entry
Conditions, from the studies’ own filings
- Hypoparathyroidism, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.